Descrizione del progetto
Nuovo trattamento farmacologico per l’alcolismo
L’alcolismo o il disturbo da uso di alcol (DUA) è una delle principali preoccupazioni in tutta l’UE e nel mondo intero. Il trattamento di solito prevede un difficile processo di disintossicazione che richiede un supporto fisico e mentale per aiutare il paziente a rinunciare all’alcool. Le terapie farmacologiche attuali non sono ottimali e possono provocare gravi effetti collaterali. Il progetto StopAddict, finanziato dall’UE, si sta preparando a invertire questa tendenza. Tale progetto porterà sul mercato un nuovo farmaco denominato KT-110. Sviluppato dall’azienda francese Kinnov-Therapeutics, questo nuovo farmaco di prima classe consentirà ai pazienti di controllare il proprio consumo di alcol. L’efficacia di KT-110, dopo 20 anni di ricerca e sviluppo preclinico, è correlata alla sua azione su un percorso di recente scoperta che è fortemente implicato nella dipendenza da alcol.
Obiettivo
Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment.
In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009.
After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2.
Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME - SME instrumentCoordinatore
45100 Orleans
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.